40results about How to "Reduce Lipid Deposition" patented technology

The invention belongs to the technical field of medicine, and relates to applications of a benzenesulfonamido benzamide compound in preparation of medicines used for treatment of non-alcoholic fatty liver diseases. It is confirmed through study on influences on golden hamster weight and liver and kidney index, influences on the contents of ALT and AST in golden hamster serum, influences on goldenhamster serum and blood fat relates indexes, influences on the content of fat in golden hamster livers, and influences on golden hamster liver tissue pathogeny structures that the benzenesulfonamido benzamide compound possesses excellent activity in treatment of non-alcoholic fatty liver diseases, and it is promising for the benzenesulfonamido benzamide compound to be developed into medicines usedfor treatment of non-alcoholic fatty liver diseases.

The invention discloses application of novel loquat leaf sesquiterpene glycoside in relieving liver cell lipid deposition, and also discloses application in preparation of drugs and health-care foodsfor preventing or treating non-alcoholic fatty liver. The name of the sesquiterpene glycoside is nerolidol-3-O-alpha-L-arabinopyranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1-> 2)-[alpha-L-rhamnopyranosyl-(1-> 6)]-beta-D-glucopyranoside.

A dripping pill for treating DIC, coronary heart disease, angina pectoris, acute myocardiac infarction, ischemic cerebral apoplexy, hyperlipemia, etc is preportionally prepared from notoginseng and leech through extracting.

The invention relates to a traditional Chinese medicinal formula, and especially relates to a traditional Chinese medicinal formula for treating hypertension. The formula comprises 15-36g of prepared rehmannia root, 6-20g of Cornus officinalis, 6-20g of Chinese yam, 3-15g of Poria cocos, 3-20g of Rhizoma Alismatis, 3-20g of Cortex Moutan, 2-15g of tangerine pericarp, 2-15g of cassia seed, 2-10g of cinnamon and 5-15g of Achyranthes bidentata. The formula aims at the main reasons of hyperactivity of liver-yang, yang hyperactivity and yin deficiency of hypertension patients, and nourishes liver and kidney yin to reduce lipid deposition on aorta walls, reduce blood fat and improve kidney functions in order to reduce the blood pressure. The above formula also has blood sugar reducing, liver cell protecting and tumor preventing effects, realizes simultaneous treatment of principal and subordinate symptoms, and has no toxic or side effects. When the formula is clinically taken by 236 patients, the effective rate is 100%, and the cure rate is 93.6% or above.

The invention discloses a traditional Chinese medicine preparation for treating the fatty liver. The traditional Chinese medicine preparation is prepared from effective ingredients and medically acceptable auxiliary materials. The effective ingredients comprise, by weight, 5%-30% of codonopsis pilosula, 5%-30% of rhizoma alismatis, 5%-30% of the root of kudzu vine, 4%-10% of panax notoginseng, 5%-25% of the root of red-rooted salvia, 5%-15% of pollen typhae, 5%-30% of prepared fleece flower roots, 5%-30% of serrate rabdosia herb and 5%-30% of serrate rabdosia herbs. Codonopsis pilosula in the traditional Chinese medicine preparation can invigorate the spleen to eliminate dampness and serves as a monarch drug. Rhizoma alismatis, the root of kudzu vine and serrate rabdosia herb can resolve dampness and relieve internal heat of fever, and panax notoginseng, the root of red-rooted salvia and pollen typhae can promote blood circulation to remove blood stasis and serve as a ministerial drug. Prepared fleece flower roots can tonify the kidney and nourish the lever, lychee seeds can promote the circulation of qi and remove stasis and serves as an adjuvant drug, the nine kinds of medicine are used together, the functions of invigorating the spleen to eliminate dampness and invigorating the circulation of blood and tonifying the kidney are achieved together, then liver lipidosis is restrained, liver fat is promoted to be degraded, liver lipidosis is reduced, and the remarkable curative effect on the fatty liver is achieved.

The invention discloses a novel application of rhizoma cimicifugae and an extract thereof. According to the invention, it is discovered that the rhizoma cimicifugae, an alcohol extract of the rhizomacimicifugae and an ethyl acetate phase extract of the rhizoma cimicifugae are obvious in weight losing and blood glucose reducing effects, and weight losing and blood glucose reducing effects of a natural compound, namely actinodaphnine, in the ethyl acetate phase extract of the rhizoma cimicifugae are confirmed. The actinodaphnine is a 9,19-cycloartane triterpenoid saponin compound. Based upon animal experiments, it is proved that the actinodaphnine can prevent the formation of obesity induced by high fat diets, and moreover, the actinodaphnine can treat the formed obesity induced by high fatdiets and can improve obesity-related sugar intolerance, insulin resistance and hepatic injury. The rhizoma cimicifugae, the alcohol extract of the rhizoma cimicifugae, the ethyl acetate phase extract of the rhizoma cimicifugae and the actinodaphnine can be used for preparing medicines or health-care products for losing weight, reducing blood glucose and protecting liver.

The invention discloses application of the polysaccharide of the flowers of Apios americana Medikus to reduction of lipidosis in hepatocytes. A preparation method for the polysaccharide of the flowersof Apios americana Medikus comprises the following steps: 1) preparation of a crude polysaccharide product of the flowers of Apios americana Medikus: mixing the flowers of Apios americana Medikus with distilled water, carrying out extraction at first, then carrying out smashing, centrifugation and concentration, adding ethanol in the obtained concentrate until the final concentration of ethanol is 80 +/- 5%, carrying out standing at 4 +/- 1 DEG C for 24 +/- 2 h, and then collecting a precipitate so as to obtain the crude polysaccharide product of the flowers of Apios americana Medikus; and 2)purification of the crude polysaccharide product of the flowers of Apios americana Medikus: subjecting the crude polysaccharide product of the flowers of Apios americana Medikus to decoloring with active carbon and Sevage-process deproteinization.

The invention discloses application of a taro tuber ethanol extract in reducing liver cell lipidosis. The application refers to preparation of medicines and healthcare foods for treating or preventingnon-alcoholic fatty liver diseases. A preparation method of the taro tuber ethanol extract comprises the following steps: mixing taro tubers with 95% ethanol with 0.1mol/L of hydrochloric acid, pulping, performing ultrasonic extraction, and centrifuging to obtain supernate; concentrating the supernate, and performing separation purification on the obtained concentrated liquid with macroporous resin; using a 1% formic acid solution as an eluting agent and a methanol solution with 0.2% of formic acid as an eluent, and collecting an elution liquid; concentrating the elution liquid, pre-freezingthe pulp concentrated liquid at minus 70 DEG C to minus 90 DEG C firstly, and further drying by a vacuum freeze-drying machine, thereby obtaining powder, namely the taro tuber ethanol extract.

The invention relates to an application of KLF4-based salidroside to resisting vascular endothelial cell senescence, in particular to an application of salidroside to respects of endothelial cells damage caused by Hcy, restraining of active oxygen level rise induced by Hcy, preparations for resisting vascular endothelial cell senescence and the like. The result indicates that the salidroside exerts important effects in the endothelial cells senescence induced by Hcy, and the mechanism of the salidroside is mainly based on adjustment and control of a transcription factor KLF4.

The present invention belongs to the technical field of tea applications, specifically relates to an application of exocarpium citrus grandis tea, and more specifically relates to the application of the exocarpium citrus grandis tea in preparing medicines or food for relieving non-alcoholic fatty liver. The exocarpium citrus grandis tea is applied in preparation of products for relieving the non-alcoholic fatty liver, especially the application of the exocarpium citrus grandis tea in the preparing the medicines/food for relieving the non-alcoholic fatty liver, which is the key protection scopeof the present invention. The exocarpium citrus grandis tea is any one of exocarpium citrus grandis black tea, exocarpium citrus grandis yellow tea and exocarpium citrus grandis green tea. The provided exocarpium citrus grandis tea can significantly reduce lipid deposition in a HepG 2 cell model, can up-regulate p-AMPK/AMPK, p-ACC/ACC and CPT-1 to promote lipid oxidation by regulating an AMPK signaling pathway, down-regulates expressions of SREBP1c and FAS proteins to inhibit fat synthesis, so as to reduce fat deposition in liver cells, so that the non-alcoholic fatty liver disease caused byhigh-fat diet, bad habits, etc. can be improved and the exocarpium citrus grandis tea has an obvious function for relieving the non-alcoholic fatty liver.

The invention discloses an application of formononetin to treatment of nonalcoholic fatty liver disease. An in vitro and an in vitro cell model are adopted, formononetin is used for treating animals,and the improvement effect of the formononetin on metabolic syndromes of nonalcoholic fatty liver, obesity, insulin resistance, lipid disorders and the like can be observed. Experiment proves that theformononetin can notably reduce weight, liver weight/body mass indexes, liver triglyceride(TG), liver lipidoses, liver function damage criterion-millet straw aminopherase (AST) and alanine aminotransferase (ALT) of organisms suffering from nonalcoholic fatty liver, and besides, can improve insulin resistance. Blood biochemistry detection indicates that the formononetin can also reduce the level of triglyceride (TG), cholesterol (TC) and low intensity lipoprotein (LDL-C) of HFD mice, and can improve the lipid disorders. The formononetin has important effects on treatment of nonalcoholic fattyliver.

The invention discloses application of taro leaf alcohol extract in reducing hepatic cell lipidosis and preparation for drug and healthcare food for treating or preventing the non-alcoholic fatty liver disease. A preparation method for the taro leaf alcohol extract comprises the following steps: mixing and pulping taro leaves and 85% alcohol containing 0.1 mol/L of hydrochloric acid, ultrasonically extracting and centrifuging to obtain liquid supernatant; rotatably evaporating and concentrating the liquid supernatant in a rotary evaporator; and separating and purifying concentrated solution through macroporous resin, taking an methanol aqueous solution containing 0.05% of formic acid as an eluent; rotatably evaporating and concentrating eluant, pre-freezing the slurry concentrated solution, drying the slurry into powder through a vacuum-freezing dryer, thereby obtaining taro leaf alcohol extract.

The invention belongs to the technical field of molecular biology, and particularly relates to a long-chain non-coding RNA AAGNCR and application thereof in prediction of intramuscular fat content ofpigs. The objective existence of AAGNCR is proved through RT-PCR, and meanwhile it is proved that AAGNCR has a promoting effect on intramuscular adipose cell lipid deposition. The AAGNCR siRNA sequence for inhibiting the expression of the AAGNCR sequence is synthesized by aiming at the AAGNCR sequence, and the sequence can obviously reduce the expression quantity of the AAGNCR in cells and has anobvious inhibition effect on the expression of the AAGNCR.

The invention relates to a long-circulating ligustrazine composite injection and a preparation method thereof, wherein the preparation contains the following ingredients: ligustrazine compounds, polyunsaturated acid-enriched oil for injection, emulsifier of natural product, polyglycol derivative, vitamin E, micro element selenium, glycerol, fructose, complexing agent EDTA, a proper amount of pH value regulator and water for injection as the rest. The preparation according to the invention enhances the effect of ligustrazine compounds in preventing and treating cardiovascular diseases.

The invention provides an application of CHRNA4 in preparation of drugs for treating nonalcoholicity steathopatitis. It is disclosed by a nonalcoholicity steathopatitis (abbreviated as NASH) mice induced by high-fat and high-sugar diets that the CHRNA4 can be used as a potential therapeutic target of the NASH, and the therapeutic effect of the antagonist lobelin hydrochloride of the CHRNA4 on theNASH is proved to provide a new way to treat the NASH.

The invention belongs to the technical field of oral spray, and particularly relates to an oral spray for losing weight, which comprises the following raw materials: 8-16 parts of chieh-qua, 8-16 parts of garcinia cambogia peel, 8-16 parts of gymnema sylvestre leaves, 5-15 parts of yellow cherry pepper, 5-10 parts of guarana, 4-10 parts of apios americana medikus leaves, 4-10 parts of paper mulberry leaves, 4-7 parts of red raspberry, 4-7 parts of fructus piperis longi, 3-8 parts of cleistocalyx operculatus, 3-8 parts of grifola frondosa, 3-8 parts of cornflower and 1-3 parts of menthol. After chieh-qua, garcinia cambogia peel, gymnema sylvestre leaves, yellow cherry peppers, guarana, apios americana medikus leaves, paper mulberry leaves, red raspberry, fructus piperis longi, cleistocalyx operculatus, grifola frondosa, cornflowers and menthol are combined together to form the oral spray, carbohydrates in various foods can be inhibited from being converted into fat in vivo, fat metabolism can be improved, carbohydrate metabolic balance can be adjusted, absorption of saccharides in small intestines can be inhibited, blood sugar can be stabilized, hunger sensation can be delayed, basic energy daily required by the body can be supplied and supplemented, the physical ability level can be enhanced and the health-care weight-losing effect can be comprehensively realized from multiple angles.

The invention discloses an application of an AKT2 inhibitor in the preparation of a medicine for treating a non-alcoholic fatty liver disease, and belongs to the technical field of biological medicines. Pharmacological experiment results prove that the AKT2 inhibitor (CCT128930) has a good treatment effect on an L02 cell lipid deposition model induced by free fatty acid for the first time, lipid deposition in cells and ROS level in cytoplasm are reduced, and Caspase 3 enzyme activity can be reduced, so that cell apoptosis caused by free fatty acid is reduced. The AKT2 inhibitor is used for preparing the medicine for treating the non-alcoholic fatty liver disease, the curative effect is definite, the effect is obvious, the side effect is low, and the medical application prospect is wide.